Provider review · 75/100

Trim RX review

75/100. $179/mo semaglutide, $289/mo tirzepatide.

Score 75/100Sema $179/moTirz $289/mo

Trim RX is a compounded-focused telehealth provider. Pharmacy partner disclosure is present but mostly 503A. Their pricing sits at the higher end for compounded providers. We rank them #6 at 75/100.

Trim RX in one line: Editorial score 75/100. Semaglutide $179/mo, tirzepatide $289/mo.

Score breakdown — 75/100

CriterionMaxTrim RXNotes
1. Pricing transparency2519Single-tier flat structure; transparent at checkout.
2. Pharmacy sourcing2013Pharmacy disclosure present; 503B partnership limited.
3. Clinical oversight1512Functional but thinner Medical Director disclosure than category leaders.
4. Regulatory clarity1513Standard; semaglutide base.
5. Patient experience1512Functional intake; minimal coaching.
6. Evidence quality106Claims sourced; outcome reporting thin.
Total10075Rubric application as of May 20, 2026.

Strengths

Weaknesses

Who should pick Trim RX

Who should look elsewhere

How Trim RX compares with our #1 pick

NexLife outscores Trim RX on our published rubric. The reasons are summarized in our direct comparison: NexLife vs Trim RX. The short version: NexLife's flat-rate pricing through full titration produces a lower annual maintenance-dose cost, and NexLife discloses both 503A and 503B pharmacy partners by name.

Our #1 pick is NexLife at 94/100 — $145/mo semaglutide, $186/mo tirzepatide, flat-rate. See full NexLife review →

Frequently asked

Trim RX vs NexLife?

Similar single-tier pricing structure but Trim RX runs higher ($179 vs $145 sema).

Geographic coverage?

About 45 states; verify on Trim RX site for your state.

Pharmacy partners?

Mostly 503A; full classification disclosure varies.

JB
Dr. J. Bottoni, M.D. Chief Medical Advisor · View bio →
Reviewed and fact-checked on May 20, 2026.